GSK rejects idea of buying AstraZeneca
LONDON May 3 (Reuters) - Britain's biggest drugmaker GlaxoSmithKline has no interest in buying its smaller British rival AstraZeneca, GSK's chief executive said on Thursday.
AstraZeneca's future is in flux, following the planned early exit of its CEO David Brennan from June 1, leading some analysts to speculate it might become a takeover target.
GSK CEO Andrew Witty, however, told shareholders at the company's AGM that buying a big company like AstraZeneca would be "very distracting".
- Insight: How U.S. spying cost Boeing multibillion-dollar jet contract
- Exclusive: Secret contract tied NSA and security industry pioneer |
- With Fed out of the way, what's next on Wall Street?
- Insight: For Chinese farmers, a rare welcome in Russia's Far East
- Millions of Target shoppers face new debit card limits |